icon-folder.gif   Conference Reports for NATAP  
60th Annual Meeting of the American Association for the Study of Liver Diseases
Boston, MA, Hynes Convention Center
October 30-November 3, 2009
Back grey_arrow_rt.gif
Prevalence and Characteristics of Hepatitis B Virus Mutations in Chronic Hepatitis B Patients on Oral Antiviral Therapy: The CHARM Study
  Reported by Jules Levin
AASLD Oct 31-Nov 3 2009, Boston, MA
SK Roberts1, MC Ngu2, SI Strasser3, J George4, GJ Dore5, SA Locarnini6, JJ Sasadeusz7, W Sievert8, K Mitchell9 and AM Elsome9 for the CHARM Study Group 1The Alfred Hospital, Prahran, VIC; 2Concord Repatriation General Hospital, Concord, NSW; 3Royal Prince Alfred Hospital, Camperdown, NSW; 4University of Sydney at Westmead Hospital, Westmead, NSW; 5National Centre in HIV Epidemiology & Clinical Research, UNSW, Darlinghurst, NSW; 6Victorian Infectious Diseases Reference Laboratory, North Melbourne, VIC; 7Royal Melbourne Hospital, Parkville, VIC; 8Monash Medical Centre, Clayton, VIC; 9Gilead Sciences Pty Ltd, East Melbourne, VIC.
The aim of the study was to describe the prevalence and nature of hepatitis B virus (HBV) mutations that confer drug resistance in patients receiving AVT in a tertiary clinic outpatient setting in Australia


The advent of newer, more potent oral antiviral therapies (AVT) has been a significant advance in the treatment of chronic hepatitis B (CHB)
However, long-term management of CHB may be compromised by the emergence of drug-resistant mutations (genotypic resistance) that may lead to virologic breakthrough and progressive liver disease
Detection of genotypic resistance:
- Facilitates treatment modifi cation before viral or clinical rebound
- prevents the initiation of inappropriate, cross-resistant AVT
However, resistance testing is not routine